AGIOS PHARMACEUTICALS, INC. (AGIO)

27.82 0 (0%)

As of 2026-02-17 17:28:17 EST

Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 (or 2007) by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013.: Table 1

Traded asNasdaq: AGIO
ISINUS00847X1046
CIK0001439222
LEI529900ONJHY8EOGYT555
EIN—
Sector—
IndustryPharmaceutical Preparations
CEOBrian Goff
Employees536
Fiscal Year End1231
Address88 SIDNEY STREET, CAMBRIDGE, MA, 02139
Phone617-649-8600
Websitehttp://agios.com
Stock Quotes
trading_symbolregistrant_nametimepricechangepercentage_change
AGIOAGIOS PHARMACEUTICALS, INC.2026-02-17 17:28:1727.8200
This is a preview of the latest data. Subscribe to access the full data.
Company Information
trading_symbolcentral_index_keyregistrant_nameisin_numberlei_numberein_numberexchangesic_codesic_descriptionfiscal_year_endstate_of_incorporationaddress_streetaddress_cityaddress_stateaddress_zip_codeaddress_countryaddress_country_codephone_numbermailing_addressbusiness_addressformer_nameindustryfounding_datechief_executive_officernumber_of_employeeswebsitemarket_capshares_issuedshares_outstandingdescriptionupdate_time
AGIO0001439222AGIOS PHARMACEUTICALS, INC.US00847X1046529900ONJHY8EOGYT555—Nasdaq2834Pharmaceutical Preparations1231DE88 SIDNEY STREETCAMBRIDGEMA02139UNITED STATESUS617-649-860088 SIDNEY STREET, CAMBRIDGE, MA, 0213988 SIDNEY STREET, CAMBRIDGE, MA, 02139AGIOS PHARMACEUTICALS INC—2008Brian Goff536http://agios.com1,914,339,20174,665,00358,592,172Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 (or 2007) by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013.: Table 12026-02-12 17:38:16
This is a preview of the latest data. Subscribe to access the full data.
AGIO Stock Price (End-of-Day)
This is a preview of the latest data. Subscribe to access the full data.
AGIO Stock Price (1-Minute)
This is a preview of the latest data. Subscribe to access the full data.
Market Cap
Fiscal YearMarket CapChange In Market CapPercentage Change In Market CapShares OutstandingChange In Shares OutstandingPercentage Change In Shares Outstanding
20251,914,339,201-501,821,999-20.769458,592,1721,296,0052.2619
20242,416,161,200858,375,87455.102357,296,1671,101,3201.9598
20231,557,785,326357,507,82229.785456,194,847909,6241.6453
This is a preview of the latest data. Subscribe to access the full data.
Executive Compensation
Executive NameExecutive PositionFiscal YearSalaryBonusStock AwardsIncentive Plan CompensationOther CompensationTotal Compensation
James BurnsChief Legal Officer2024511,9170548,590287,95415,8612,432,507
Sarah GheuensChief Medical Officer2024583,4950548,590328,21615,8612,544,347
Brian GoffChief Executive Officer2024822,19801,742,580719,42311,6536,776,359
Cecilia JonesChief Financial Officer2024503,8800548,590283,43315,2612,419,349
Tsveta MilanovaChief Commercial Officer2024525,3000548,590295,48215,8612,453,418
This is a preview of the latest data. Subscribe to access the full data.
Employee Count
Fiscal YearEmployee Count
2025539
2024486
2023383
This is a preview of the latest data. Subscribe to access the full data.
Income Statements
Fiscal Year202520242023
Revenue54,028,00036,498,00026,823,000
Cost Of Revenue6,345,0004,165,0002,881,000
Gross Profit———
Research And Development Expenses339,535,000301,286,000295,526,000
General And Administrative Expenses180,280,000156,784,000119,903,000
Operating Expenses526,160,000462,235,000418,310,000
Operating Income-472,132,000-425,737,000-391,487,000
Net Income-412,781,000673,725,000-352,088,000
Earnings Per Share Basic-7.1211.86-6.33
Earnings Per Share Diluted-7.1211.64-6.33
Weighted Average Shares Outstanding Basic57,972,00456,807,41555,651,487
Weighted Average Shares Outstanding Diluted57,972,00457,889,25555,651,487
This is a preview of the latest data. Subscribe to access the full data.
Balance Sheet Statements
Fiscal Year202520242023
Cash And Cash Equivalents89,130,00076,247,00088,205,000
Marketable Securities Current765,295,000817,463,000688,723,000
Accounts Receivable10,577,0004,109,0002,810,000
Inventories32,920,00027,616,00019,076,000
Non Trade Receivables—900,0001,100,000
Other Assets Current———
Total Assets Current942,052,000965,600,000833,835,000
Marketable Securities Non Current310,013,000638,321,00029,435,000
Property Plant And Equipment10,775,00011,675,00015,382,000
Other Assets Non Current3,931,0004,724,0004,057,000
Total Assets Non Current355,173,000697,599,000103,283,000
Total Assets1,297,225,0001,663,199,000937,118,000
Accounts Payable18,355,00016,643,0009,780,000
Deferred Revenue———
Short Term Debt———
Other Liabilities Current45,459,00046,861,00043,167,000
Total Liabilities Current82,206,00081,156,00067,955,000
Long Term Debt———
Other Liabilities Non Current90,000880,0001,156,000
Total Liabilities Non Current21,905,00041,087,00058,144,000
Total Liabilities104,111,000122,243,000126,099,000
Common Stock75,00073,00072,000
Retained Earnings-561,705,000-148,924,000-822,649,000
Accumulated Other Comprehensive Income———
Total Shareholders Equity1,193,114,0001,540,956,000811,019,000
This is a preview of the latest data. Subscribe to access the full data.
Cash Flow Statements
Fiscal Year202520242023
Depreciation And Amortization5,200,0005,700,0006,600,000
Share Based Compensation Expense52,552,00042,847,00044,766,000
Other Non Cash Income Expense-5,00039,000-553,000
Change In Accounts Receivable6,468,0001,299,000604,000
Change In Inventories5,304,0008,540,00010,584,000
Change In Non Trade Receivables———
Change In Other Assets———
Change In Accounts Payable1,746,0006,601,000-8,733,000
Change In Other Liabilities-790,000-276,000-2,123,000
Cash From Operating Activities-372,977,000-389,841,000-296,062,000
Purchases Of Marketable Securities641,759,0001,542,433,000417,930,000
Sales Of Marketable Securities1,033,259,000818,383,000674,679,000
Acquisition Of Property Plant And Equipment4,316,0001,685,000999,000
Acquisition Of Business———
Other Investing Activities———
Cash From Investing Activities377,184,000363,441,000239,575,000
Tax Withholding For Share Based Compensation———
Payments Of Dividends———
Issuance Of Common Stock———
Repurchase Of Common Stock———
Issuance Of Long Term Debt———
Repayment Of Long Term Debt———
Other Financing Activities8,676,00014,442,0005,433,000
Cash From Financing Activities8,676,00014,442,0005,433,000
Change In Cash12,883,000-11,958,000-51,054,000
Cash At End Of Period89,130,00076,247,00088,205,000
Income Taxes Paid628,00043,150,0001,569,000
Interest Paid———
This is a preview of the latest data. Subscribe to access the full data.
Key Metrics
Fiscal Year202520242023
Earnings Per Share-7.1211.86-6.33
Price To Earnings Ratio-3.8232.7707-3.5182
Earnings Growth Rate-160.0337-287.361849.6454
Price Earnings To Growth Ratio0.0239-0.0096-0.0709
Book Value Per Share20.580927.12614.5732
Price To Book Ratio1.32261.21141.5281
Ebitda-406,953,000722,575,000-343,919,000
Enterprise Value———
Dividend Yield———
Dividend Payout Ratio———
Debt To Equity Ratio———
Capital Expenditures4,300,0001,993,000-1,005,000
Free Cash Flow-377,277,000-391,834,000-295,057,000
Return On Equity-0.3460.4372-0.4341
One Year Beta0.92481.58391.1323
Three Year Beta1.11791.45471.2891
Five Year Beta1.22611.08271.0962
This is a preview of the latest data. Subscribe to access the full data.
Insider Transactions
Insider NameRelationship To IssuerTransaction DateAmount Of SecuritiesAcquired Or DisposedSecurities Owned Following Transaction
Milanova TsvetaChief Commercial Officer2026-01-058,475A37,665
Milanova TsvetaChief Commercial Officer2026-01-052,872D34,793
Milanova TsvetaChief Commercial Officer2026-01-058,475D0
Milanova TsvetaChief Commercial Officer2025-12-306,000A32,122
Milanova TsvetaChief Commercial Officer2025-12-302,932D29,190
This is a preview of the latest data. Subscribe to access the full data.
House Trading
Name Of Reporting PersonReport DateStateTransaction TypeTransaction DateOwner TypeAmount
Gilbert Cisneros2026-01-12CA31Purchase2025-12-11—$1,001 - $15,000
Gilbert Cisneros2025-05-06CA31Purchase2025-04-17—$1,001 - $15,000
Gilbert Cisneros2025-02-11CA31Purchase2025-01-29—$1,001 - $15,000
Josh Gottheimer2024-02-15NJ05Purchase2024-01-24Joint$1,001 - $15,000
Thomas MacArthur2015-06-07NJ03Sale2015-05-27Joint$1,001 - $15,000
This is a preview of the latest data. Subscribe to access the full data.
Institutional Holdings
Investor NamePeriod Of ReportMarket ValueAmount Of SecuritiesPrice Per Security
Freestone Grove Partners LP2025-12-311,111,69240,84127.22
Caligan Partners LP2025-12-312,449,80090,00027.22
ADAR1 Capital Management, LLC2025-12-315,117,360188,00027.22
AQR CAPITAL MANAGEMENT LLC2025-12-31754,00227,92627
Palo Alto Investors LP2025-12-315,784,223212,49927.22
This is a preview of the latest data. Subscribe to access the full data.
Mutual Fund Holdings
Registrant NamePeriod Of ReportFund NameFund SymbolAmount Of UnitsValue In UsdPercentage Value Compared To Assets
Global X Funds2025-11-30Global X Aging Population ETFAGNG7,249211,670.80.2786
ALPS ETF Trust2025-11-30ALPS Medical Breakthroughs ETFSBIO25,453743,227.60.7105
SEI INSTITUTIONAL INVESTMENTS TRUST2025-11-30SIIT Extended Market Index Fund - Class ASMXAX7,900230,6800.0191
SEI INSTITUTIONAL INVESTMENTS TRUST2025-11-30SIIT Multi-Asset Real Return Fund - Class ASEIAX2296,686.80.0009
Invesco Exchange-Traded Self-Indexed Fund Trust2025-11-30Invesco Russell 2000(R) Dynamic Multifactor ETFOMFS4,311125,881.20.0488
This is a preview of the latest data. Subscribe to access the full data.